Skip to main content
OpenTrials
Completed

NCT Number: NCT03864549

The Effect of Oral Probiotics on Glycemic Control of Women With Gestational Diabetes Mellitus

Scientific background: Uncontrolled gestational diabetes mellitus (GDM) is associated with severe maternal and neonatal morbidities. Treatment of GDM is multidisciplinary and includes lifestyle changes and medications. However, the efficacy of these treatments is limited due to poor motivation, daily painful blood tests and multiple injections.

Probiotic supplements were shown to modulate the gut microbiome by reducing the adverse metabolic effects associated with pathogenic microbial colonization. Promising effects on glycemic control and insulin resistance in non-pregnant diabetic patients were reported. However, the effect of probiotics on glycemic control in GDM has not been elucidated.

Objectives: To examine the effect of a mixture of probiotic strains given daily on maternal glycemic parameters, and pregnancy outcomes among women with GDM.

Working hypothesis: Oral administration of probiotics will be effective in glucose control of patients with GDM and their neonates without causing significant adverse effects.

Type of research and methods of data collection: A prospective randomized, double blind, placebo controlled trial. Women newly diagnosed with GDM will be recruited and followed in the GDM clinic and Maternal-Fetal Medicine ward (including the research clinic) at Emek Medical Center. They will be divided into a research group, receiving the probiotic formula Femina II and a control group, receiving a placebo (2 capsules/day) until delivery. Glycemic control will be evaluated by daily glucose charts. After 2 weeks of diet and probiotic/placebo treatment and thereafter, pharmacotherapy will be started in case of poor glycemic control according to the daily glucose charts. Blood tests for glycated molecules will be performed. Fetal well-being and growth will be assessed. The primary outcomes are:

1. The rate of women requiring medications for glycemic control 2. Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Assuta-Ashdod medical center, Ashdod, Israel

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women who were diagnosed with GDM from 13 to 32.6 gestational weeks
  • 18 years old and older
  • Singleton pregnancy

Exclusion criteria

  • Women with pre-gestational diabetes mellitus
  • GDM diagnosed ≥ 33 gestational weeks
  • Women using prophylactic antimicrobial treatment
  • Immunocompromised women
  • Multiple pregnancy
  • Women taking oral probiotic products who refuse to stop the consumption (food-containing probiotics is not considered an exclusion criterion).

Treatment and study plan

Femina II

Dietary Supplement

2 capsules per day until delivery

Placebo

Other

2 capsules per day until delivery

Primary outcomes

  1. The rate of women who will require pharmacotherapy for glycemic control.

    Time frame: During the length of pregnancy (up to 9 months)

  2. Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.

    Time frame: 2 weeks

Secondary outcomes

  1. The rate of women with controlled diabetes

    Time frame: During the length of pregnancy (up to 9 months)

  2. Mean daily glucose charts

    Time frame: During the length of pregnancy (up to 9 months)

  3. Mean daily pre-prandial glucose values

    Time frame: During the length of pregnancy (up to 9 months)

  4. Mean daily post-prandial glucose values

    Time frame: During the length of pregnancy (up to 9 months)

  5. Level of glycated molecules

    Time frame: During the length of pregnancy (up to 9 months)

  6. The rate of women with mean pre-prandial values ≥ 95 mg/dl, mean post-prandial values ≥ 130 mg/dl, and mean daily glucose > 100 mg/dl

    Time frame: During the length of pregnancy (up to 9 months)

  7. The rate of cesarean deliveries

    Time frame: At delivery

  8. The rate of labor inductions

    Time frame: At delivery

  9. The rate of birth weight≥4000 gr

    Time frame: At delivery

  10. The rate of birth weight> 90th percentile

    Time frame: At delivery

  11. The rate of admission to the neonatal intensive care unit

    Time frame: Within a week from delivery

  12. Apgar score at 1 and 5 minutes from birth

    Time frame: Within 1-5 minutes after delivery

  13. The rate of neonatal hypoglycemia

    Time frame: Within 1-2 days after delivery

  14. The rate of neonatal hyperbilirubinemia

    Time frame: Within a week from delivery

  15. The rate of neonatal polycythemia

    Time frame: Within a week from delivery

  16. The rate of neonatal hypocalcemia

    Time frame: Within a week from delivery

  17. The rate of neonatal hypomagnesemia

    Time frame: Within a week from delivery

  18. Cord blood pH levels

    Time frame: At delivery

  19. The rate of neonatal malformations and developmental disorders

    Time frame: 1-2 days after delivery

  20. birth weight

    Time frame: At delivery

  21. Head circumference

    Time frame: 1-2 days after delivery

  22. Maternal adverse effects

    Time frame: During the length of pregnancy (up to 9 months)

  23. Duration of time until pharmacotherapy for glycemic control is indicated

    Time frame: During the length of pregnancy (up to 9 months)

Sponsors and collaborators

Lead sponsor

HaEmek Medical Center, Israel

Other

Registry information

Official study title

The Effect of Oral Probiotics on Glycemic Control of Women With Gestational Diabetes Mellitus - Randomized, Double Blind, Placebo Controlled Trial, Phase 4

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 6, 2019
Registry last updated
Aug 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.